






































In Western societies, life expectancy has increased 
dramatically over the last century, but striking inter-
individual differences in life expectancy remain [1]. 
Ample evidence has shown that healthy longevity is 
determined by a mix of genetic, environmental and 
chance elements. Because the odds of exceptional 
longevity runs in families, we designed the Leiden 
Longevity Study [2]. Recently, we have shown that the 
nonagenarian siblings included in the Leiden Longevity 
Study displayed a 41% lower risk of mortality 
compared to sporadic nonagenarians [3]. Moreover, 
compared to their partners, the offspring of 
nonagenarian siblings displayed a significantly lower 
prevalence of myocardial infarction,  hypertension and  
 
 











































































diabetes mellitus [3]. The differences in clinical 
phenotype observed after selection for familial 
longevity are in line with the lower prevalence of 
cardio-metabolic disease previously detected when 
offspring from sporadic centenarians were compared to 
offspring of parents who had died at average age [4] and 
when offspring from sporadic centenarians were 
compared to their partners [5]. Moreover, the observed 
lower mortality rate at high ages and better preservation 
of health at middle age indicates that resilience against 
disease and death may have similar underlying 
biological mechanisms that are influenced by genetic or 
familial factors.  
 
Of the genetically determined pathways that have been 
implicated in longevity in a variety of different model 
organisms,  the evolutionarily conserved insulin/IGF-1  
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literature (reviewed in [6]). Mutations in IIS 
components were first found to affect reproduction, 
metabolism, stress response and life span in C. elegans 
(reviewed in [7]). The link between reduced IIS 
signaling and longevity was subsequently also observed 
in  D. melanogaster. Mutants in the D.  melanogaster 
insulin receptor InR  [8]  and in the insulin receptor 
substrate  CHICO  [9] are both long-lived. Strikingly 
however, in both cases the long-lived phenotype was 
only observed for females. In addition to being long-
lived, these D. melanogaster females are small, obese 
and infertile. In mice, selective disruption of the insulin 
receptor in the adipose tissue leads to a reduction in fat 
mass and extended longevity [10]. Increases in lifespan 
were also reported in mice with deletion of insulin 
receptor substrate 1 (IRS1) in whole body [11] or IRS2 
only in the brain [12]. Moreover, dwarf mice exhibiting 





-/-   [15] all 
display hypoinsulinemia and enhanced insulin 
sensitivity along with extended longevity. In mice 
heterozygous for igf1r  deletion (Igf1r
+/- [16]) or 
containing a hypomorphic igf1r mutation (Midi mice 
[11]), only females, but not males, exhibited the long-
lived phenotype.  
 
Based on the similarities among the insulin/IGF-1 
pathways in animals and humans, the possibility that 
modifications in the insulin/IGF-I signaling system 
could also extend lifespan in humans has been 
suggested. However, separating the roles of insulin and 
IGF-1 in mammals and their relevance for human 
healthy longevity has been difficult and generated much 
controversy. In humans, relatively low IGF-I levels 
have been associated with an increased risk of 
developing cardiovascular disease and diabetes, while 
relatively high IGF-I levels have been associated with 
an increased risk of developing cancer [17]. Moreover, 
in humans, an age-related decline in IGF-1 levels occurs 
[18], and at old age, low IGF-1 levels are associated 
with frailty [19], poor nutrition and cognitive decline 
[20] and an increased risk of death [21]. On the other 
hand, genetic variation in genes associated with down-
regulation of the IIS pathway has been associated with 
human longevity in several instances, although, when 
moving up the evolutionary ladder, together with an 
increase in genome complexity, effect sizes became 
smaller [22]. Two studies have shown evidence for a 
role for genetic variation in the IIS pathway in body 
height as well as human longevity. First, earlier we 
found an association between genetic variation 
associated with reduced IIS pathway activity and 
shorter stature as well as improved old age survival in 
sporadic female octogenarians [23]. Second, offspring 
of sporadic female centenarians were shown to be 
smaller and display higher IGF-1 levels, indicative of 
IGF-1 insensitivity, while rare IGF-1R mutations 
associated with IGF-1 insensitivity were found enriched 
in centenarians [24]. Here, to investigate whether these 
results could be generalized to familial longevity, we 
have compared key anthropometric measures as well as 
serum parameters related to insulin/IGF-1 signaling in a 
group of middle-aged offspring of nonagenarian 
siblings and a control group of their partners of the 




Metabolic characteristics of offspring compared to 
partners 
 
Table 1 depicts the demographic and metabolic 
characteristics of the groups from the Leiden Longevity 
Study that were used for the present study. The group of 
offspring proportionately contained less diabetics than 
the group of partners (p = 0.001). After exclusion of 
diabetics, the group of offspring had lower non-fasted 
serum levels of glucose (p = 0.002) than the group of 
partners.  In addition, the group of offspring had a 
slightly more favorable lipid profile as compared to the 
group of partners.   
 
IGF-1/IGFBP3 and non-fasted glucose 
 
Next we assessed whether the lower glucose levels 
observed among the group of offspring relative to the 
group of partners could be driven by differences in IGF-
1 axis parameters.  Therefore we determined the 
association between serum IGF-1 / IGFBP3 molar ratios 
and non-fasted serum glucose levels. Higher ratios of 
IGF-1/ IGFBP3 were associated with lower serum 
glucose levels. One standard deviation increase in IGF-
1/IGFBP3 ratio was associated with a decrease of 0.10 
mmol/L serum glucose (SE: 0.05) among the group of 
partners (p = 0.05). The difference between partners and 
offspring in the change of glucose levels per standard 
deviation IGF-1/IGFBP3 ratio was not significant: 0.02 
(SE: 0.06) nmol/L per year (p for interaction = 0.70). 
 
Measures of the IGF-1 axis in offspring compared to 
partners 
 
Table 2 shows the comparison between the groups of 
offspring and partners for various IGF-1 axis 
parameters for males and females separately. In order to 
detect the effect of possible genetic differences in IGF-1 
signaling between offspring and partners, we also 
determined anthropometrical characteristics in subjects 
of both study groups (Table 2). With regard to serum 
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between the group of offspring and the group of 
partners in both sexes. Likewise, the study groups 
showed no differences in terms of sex-specific body 
stature, i.e. height, weight and body mass index. 
 
Next, we determined whether the distribution of serum 
IGF-1 axis parameters and anthropometrical parameters 















































displays the cumulative distributions of IGF-1, IGFBP3 
and height among partners and offspring for both sexes 
separately. No differences in height were observed 
between offspring and partners in the tails of the IGF-1 
and IGFBP3 distribution curves. Taken together, the 
cumulative distribution curves do not suggest enrich-
ment of high or low IGF-1 axis parameters nor large or 
short statures among the groups of offspring versus 





































  Offspring Partners  p-value 
Demographics*      
   Participants - n  1171  542   
   Diabetics – n (%)  46 (3.9)  42 (7.7)  0.001 














302 (55.7)  0.57 
   Age– (years)  59.2 (55.0 – 64.1)  58.8 (54.3 – 63.7)  0.15 
      
Serum parameters (non-diabetics)*       
   Participants - n  1125  500   
   Glucose  (mmol/L)   5.69 (5.62 – 5.76)  5.87 (5.76 – 5.97)  0.002 
   Insulin  (mU/L )**  14.4 (13.6 - 15.4)  15.4 (14.0 -16.8)  0.21 
      
  Total cholesterol  (mmol/L)†  5.56 (5.47 – 5.65)  5.62 (5.52 - 5.72)  0.40 
   LDL cholesterol (mmol/L)†  3.32 (3.24 - 3.39)  3.37 (3.29 - 3.45)  0.33 
   HDL cholesterol  (mmol/L)†  1.46 (1.42 - 1.49)  1.43 (1.39 - 1.47)  0.24 
   Triglycerides (mmol/L) **,†  1.50 (1.44 – 1.55)  1.57 (1.50 – 1.65)  0.09 
























































IGF-1 levels have been consistently reported to 
progressively decline with age. To determine whether 
this observation applied to the groups that were used in 
the present study, we assessed the association between 
serum IGF-1 levels and serum IGFBP3 levels with age. 
Figure 2 displays the sex-specific serum IGF-1 and 
IGFBP3 levels for different age categories among 
offspring and partners.  Serum IGF-1 levels declined with 
age in both female partners (-0.14 (SE: 0.04) nmol per 


















































0.05) nmol/L per year increase; p =0.001). The difference 
in annual change in serum IGF-1 levels between partners 
and offspring was not significant: 0.01 (SE: 0.05) nmol/L 
per year (p for interaction= 0.79) for females and 0.01 
nmol/L (SE: 0.06) per year (p for interaction=0.83) for 
males. Similarly, no differences between partners and 
offspring were observed in terms of annual change in 
serum IGFBP3 levels: 0.01 mg/L (SE: 0.01) (p for 
interaction = 0.47) for females and 0.02 mg/L (SE: 0.01) 













































The main findings of this study are twofold. First, 
consistent with the lower prevalence of diabetes 
observed earlier, non-fasted serum glucose levels were 
lower in the offspring of familial nonagenarians when 
compared to their partners. Second, we did not observe 
differences in non-fasted serum levels of IGF-1, 
IGFBP3 or in height between the groups of offspring 
and partners, nor in the rate of the decline of levels of 
IGF-1 or IGFBP3 over chronological age. Taken 













































Offspring* Partners*  p-value 
 
 
associated with differences in glucose handling, which 
are not explained by major differences in IGF-1 and/or 
IGFBP3 levels. 
 
The link between reduced IIS activity and longevity is 
evolutionarily conserved from worms to rodents, with 
effects on longevity often being stronger in the female 
sex. However, separating the roles of insulin and IGF-1 
in mammals has been very difficult and generated much 
controversy. Because the actions of GH, insulin and 
IGF-1 are largely interwoven, genetic modification of 
the GH/IGF-1 axis in mammals also entails differences 
Females (n)  610 286   
   IGF-1 axis serum parameters       
     IGF-1  (nmol/L)   17.1 (16.7 – 17.5)  17.1 (16.5 – 17.7)  0.99 
     IGFBP3 (mg/L)   4.44 (4.36 - 4.53)  4.47 (4.36 - 4.57)  0.72 
     IGF-1/ IGFBP3 (molar ratio)   0.11 (0.11 – 0.11))  0.11 (0.11 – 0.11)  0.60 
      
   Anthropometrics       
     Height (cm)  166.8 (166.2 – 167.3)  166.9 (166.1 – 167.7)  0.79 
     Weight (kg)  69.2 (68.2 – 70.3)  70.2 (68.9 – 71.6)  0.25 
     Body Mass Index (kg/m
2)  24.9 (24.5 – 25.3)  25.2 (24.8 – 25.7)  0.25 
      
Males (n)  515 214   
   IGF-1 axis serum parameters       
     IGF-1  (nmol/L)   17.5 (17.0 - 17.9)  17.3 (16.6 - 18.0)  0.75 
     IGFBP3 (mg/L)   4.22 (4.13 - 4.30)  4.20    (4.08 - 4.32)  0.85 
     IGF-1/ IGFBP3 (molar ratio)   0.12 (0.12 – 0.12)  0.12 (0.12 – 0.12)  0.82 
      
   Anthropometrics       
     Height (cm)  178.7 (178.1 – 179. 4)  179.1 (178.2 – 180.0)  0.44 
     Weight (kg)  82.0 (80.9 – 83.0)  82.4 (80.8 – 84.1)  0.61 
     Body Mass Index (kg/m






www.impactaging.com                   718                                        AGING, August, 2009, Vol.1 No.8in the regulation of glucose metabolism. Interestingly, 
the hallmark phenotype of all long-lived mouse models 
containing mutations that induce GH/IGF-1 deficiency 
or resistance, is their enhanced insulin sensitivity [6]. 
Previously, we observed a lower prevalence of diabetes 
in the offspring group [3]. Here, we show that after 
exclusion of all diabetics, lower non-fasted glucose 
levels were observed in the group of offspring of 
familial nonagenarians as compared to the partners. The 
lower non-fasted glucose levels in offspring compared 
to partners are suggestive of a better glucose handling 
and/or higher insulin sensitivity in familial longevity, 
which is in line with the hallmark phenotype observed 
in the many long-lived mammalian IIS mutants. Other 
data also support a link between preserved insulin 
sensitivity and human longevity. While insulin 
sensitivity generally declines with age in humans [25], 
sporadic long-lived centenarians have been shown to 
exhibit an exquisite insulin sensitivity, comparable to 



































The preserved insulin sensitivity observed in 
centenarians, co-occurred with relatively high levels of 
IGF-1/IGFBP3, which has lead to the suggestion of 
causal link between the preserved insulin sensitivity and 
levels of IGF-I/IGFBP3 [27]. In rats, IGF-1 and 
IGFBP3 were shown to have opposing (centrally 
mediated) effects on glucose metabolism, with IGF-1 
acting as an insulin sensitizer, and IGFBP3 as an insulin 
inhibitor [28]. Similarly, in humans, IGF-1 
administration was found to increase glucose uptake and 
inhibit hepatic glucose production in healthy subjects 
[29], and low serum IGF-1 levels were found associated 
with glucose intolerance [30]. In line with these findings, 
we also observed a negative association between IGF-
1/IGFBP3 levels and non-fasted glucose levels in both 
our study groups, but neither this association nor the 
mean levels of IGF-1 and IGFBP3 were different 
between the offspring and partner groups. Our obser-
vation of improved glucose handling in the absence of 






































(D).  Dark  bars  represent  offspring,  light  bars  represent  partners.  Number  of  participants  per  age  category  for  females
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contrast to model organisms, in humans, IGF-1 levels 
were not found to be decreased upon caloric restriction, 
while insulin sensitivity was increased upon caloric 
restriction in humans as in model organisms [31]. The 
lack of differences in BMI, as well as preliminary data 
on food intake, indicate however that the observed 
difference in glucose handling between the groups of 
offspring and partners can not be explained by a lower 
caloric intake in the offspring group. 
 
The observation of improved glucose handling in the 
absence of major differences in IGF-1/IGFBP3 in 
familial longevity does not rule out the possibility that 
genetic variations affecting IGF-1/IGFBP3 levels do 
contribute to human longevity. Recently, it was shown 
that centenarians exhibited a relative enrichment for rare 
genetic variants in the IGF-1 receptor which resulted in 
high levels of IGF-1/IGFBP3 coexisting with low levels 
of IGF-1 signaling [24]. Also, earlier we and others 
showed that common genetic variations affecting IGF-1 
signaling might contribute to differences in mortality in 
the population at large [23, 32], but the phenotypic 
effects associated with such variants (smaller stature, 
differences in serum levels of IGF-1 and/or IGFBP3) do 
not form a distinctive part of the hallmark phenotype of 
preserved glucose handling which we found associated 




Leiden Longevity Study. In the Leiden Longevity 
Study, 420 families were recruited consisting of long-
lived Caucasian siblings together with their offspring 
and the partners thereof [2, 23]. Families were recruited 
if at least two long-lived siblings were alive and 
fulfilled the age-criterion of 89 years or older for males 
and 91 year or older for females. There were no 
selection criteria on health or demographic 
characteristics. For 2465 of the offspring and their 
partners, non-fasted serum samples taken at baseline 
were available for the determination of endocrine and 
metabolic parameters. Between November 2006 and 
May 2008, for 2235 of the offspring and their partners, 
information on medical history was obtained from the 
participants’ general practitioner (response: 91%). For 
2255 of the offspring and their partners, information on 
the use of medication was obtained from the 
participants’ pharmacy (response: 92%). For 2184 of 
the offspring and partners a general questionnaire 
containing information on lifestyle and self-reported 
height and weight was obtained (response: 89%). For 
the present study, for a total of 1713 of the offspring 
and their partners, serum as well as information on 
medical history on diabetes and information on 
medication use and the general questionnaire were 
available (inclusion: 70%). After exclusion of subjects 
with diabetes in medical history (n=87) and/or non-
fasted glucose lower than 11 mmol/L (n=1) and/or use 
of glucose lowering medication (n=37), a sample of 
1625 subjects was available for the current study. The 
Medical Ethical Committee of the Leiden University 
Medical Centre approved the study and informed 
consent was obtained from all subjects. 
 
Biochemical analysis. All serum measurements were 
performed with fully automated equipment. For 
insulin-like growth factor-1 (IGF-1), insulin-like growth 
factor binding protein 3 (IGFBP3) and insulin, the 
Immulite 2500 from DPC (Los Angeles, CA, USA) was 
applied. CVs for these measurements were all below 
8%. For glucose, total cholesterol, HDL-cholesterol, 
triglycerides, free fatty acids (FFA) the Hitachi Modular 
or the Cobas Integra 800, both from Roche, Almere, the 
Netherlands were applied. CVs of these measurements 
were all below 5 %.  
 
Medication use. Lipid lowering agents were defined as 
fibrates, niacin, bile acid sequestrants, 3-hydroxy-3-
methylglutaryl-coenzyme A  reductase inhibitors (ATC 
code C10).  
 
Calculations and statistical analysis. For estimation of 
the level of LDL cholesterol the Friedewald formula 
was applied (LDL cholesterol [mmol/l] = total 
cholesterol - HDL cholesterol - [triglycerides/2.2]), 
whereby participants with a triglyceride concentration 
higher than 443 mg/dl (5 mmol/l) were excluded. For 
molar comparisons between IGF-1 and IGFBP3, the 
following molecular masses were used in the 
calculation: IGF-1: 7.5 kDa and IGFBP3: 28.5 kDa. 
 
Distributions of continuous variables were examined for 
normality and logarithmically transformed, when 
appropriate and used in all calculations. Geometric 
means (with 95% confidence intervals (CI)) are 
reported for transformed variables (insulin, triglycerides 
and free fatty acids). All differences in mean serum 
levels and anthropometrics between the groups of 
offspring and partners were assessed with the use of 
linear regression, adjusted for sex, age and correlation 
of sibling data using robust standard errors in STATA. 
The relation between IGF-1/IGFBP3 molar ratio 
(expressed in Z-scores and restricted to values within 3 
standard deviations (SDs) from the mean) and glucose 
was assessed with the use of a linear mixed model, 
adjusted for sex, age and correlation of sibling data in 
SPSS. The cumulative distributions of IGF-1, IGFBP3 
and height were calculated in SPSS. The change in 
levels of IGF-1, IGFBP3 over chronological age as a 
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linear mixed model, adjusted for age and correlation of 
sibling data in SPSS. The Statistical Package for the 
Social Sciences (SPSS) program for Windows, version 
14.0, and STATA version 10.0 were used for data 
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